ATOSSA THERAPEUTICS, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ATOSSA THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-06-30 was $0.00.
- ATOSSA THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-09-30 was $0.00.
- ATOSSA THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2025 was $0.00.
- ATOSSA THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $0.00.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-25 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-07 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |